

AMENDMENTS TO THE CLAIMS

Please amend the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

1. (Currently Amended) A veterinary parasitocal spot-on formulation, which comprises:
 - a) ~~a~~ veterinary parasitocidally effective amount of an ectoparasitocal combination consisting essentially of comprising an 1-N-arylpyrazole derivative, wherein the 1-N-arylpyrazole is fipronil[[,]] and amitraz; and
 - b) a pharmaceutical or veterinary acceptable liquid carrier spot-on formulation vehicle for applying the formulation to a localized region on an animal wherein the localized region is less than 10 cm² and ~~;-and-e)~~ wherein the formulation optionally includes a crystallization inhibitor.
2. (Previously presented) The parasitocal spot-on formulation according to claim 1, wherein
 - the liquid carrier vehicle comprises a solvent and a cosolvent wherein the solvent is selected from the group consisting of acetone, acetonitrile, benzyl alcohol, butyl diglycol, dimethylacetamide, dimethylformamide, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, monomethylacetamide, dipropylene glycol monomethyl ether, liquid polyoxyethylene glycols, propylene glycol, 2-pyrrolidone, diethylene glycol monoethyl ether, ethylene glycol, diethyl phthalate fatty acid esters, and a mixture of at least two of these solvents and the cosolvent is selected from the group consisting of ethanol, isopropanol and methanol
 - the crystallization inhibitor selected from the group consisting of an anionic surfactant, a cationic surfactant, a non-ionic surfactant, an amine salt, an amphoteric surfactant or polyvinylpyrrolidone, polyvinyl alcohols, copolymers of vinyl acetate and vinylpyrrolidone, polyethylene glycols, benzyl alcohol, mannitol, glycerol, sorbitol, polyoxyethylenated sorbitan esters, lecithin, sodium carboxymethylcellulose, and acrylic derivatives, and a mixture of these crystallization inhibitors.
3. (Original) The parasitocal spot-on composition according to claim 2, wherein the formulation further comprises an antioxidant.

4. (Previously presented) The parasitical spot-on composition according to claim 3, wherein the antioxidant is selected from the group consisting of butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid, sodium metabisulphite, propyl gallate and sodium thiosulphate.
5. (Original) The parasitical spot-on formulation according to claim 2, wherein water is present in a proportion of from 0 to about 30% v/v.
6. (Original) The parasitical spot-on formulation according to claim 2, wherein the crystallization inhibitor is present in an amount from about 1 to about 20% w/v.
7. (Original) The parasitical spot-on formulation according to claim 1 which comprises a crystallization inhibitor.
8. (Original) The parasitical spot-on formulation according to claim 2, wherein
- the anionic surfactant is alkaline stearates, sodium abietate; alkyl sulphates; sodium dodecylbenzenesulphonate, sodium dioctylsulphosuccinate, and fatty acids;
 - the cationic surfactant is water-soluble quaternary ammonium salts of formula $N^+R'R''R'''Y^-$ in which the radicals R independently are hydrocarbon radicals, optionally hydroxylated, and Y^- is an anion of a strong acid;
 - the amine salt is an amine salt of $N^+R'R''R'''$ in which the radicals R independently are optionally hydroxylated hydrocarbon radicals;
 - the non-ionic surfactant is optionally polyoxyethylenated sorbitan esters, polyoxyethylenated alkyl ethers, polyethylene glycol stearate, polyoxyethylenated derivatives of castor oil, polyglycerol esters, polyoxyethylenated fatty alcohols, polyoxyethylenated fatty acids, copolymers of ethylene oxide and propylene oxide; and
 - the amphoteric surfactant is lauryl-substituted betaine compounds.
9. (Original) The parasitical spot-on formulation according to claim 3, wherein the crystallization inhibitor is a crystallization inhibitor system comprising a polymeric film-forming agent and a surfactant.

10. (Original) The parasitical spot-on formulation according to claim 3, wherein the polymeric film-forming agent is polyvinylpyrrolidone, polyvinyl alcohols, or a copolymer of vinyl acetate and polyvinylpyrrolidone and the surfactant is a non-ionic surfactant.

11. (Original) The parasitical spot-on formulation according to claim 10, wherein the crystallization inhibitor system is a mixture of polyvinylpyrrolidone and polyoxethylene (20) sorbitan mono-oleate.

12-45. (Cancelled)

46. (Currently amended) The parasitocidal formulation of any one of claims 1-11, ~~23, 24 and 28~~, wherein the composition is prepared by mixing its constituents.

47. (Previously Presented) The parasitocidal formulation of claim 46 wherein each of the fipronil and amitraz is an active material, the vehicle includes a solvent as to each active material, and the mixing of the constituents of the compositions comprises each active material being mixed in the solvent as to each active material.

48. (Previously Presented) The parasitocidal formulation of claim 47 wherein there are at least two solvents.

49. (Previously Presented) The parasitocidal formulation of claim of claim 48 which includes an ester.

50. (Previously Presented) The parasitocidal formulation of claim 49 wherein the carrier includes isopropanol, ethanol, methanol, acetone, ether(s), propylene glycol, polyethylene glycol, glycol formal, di-ethylene glycol monomethyl ether (DGME), or dimethyl sulfoxide (DMSO).

51. (Previously Presented) The parasitocidal formulation of claim 1 wherein the vehicle includes DMSO.
52. (Previously Presented) The parasitocidal formulation of claim 1 wherein the vehicle includes polyvinylpyrrolidone.
53. (Previously Presented) A parasitocidal spot-on formulation of claim 1, which comprises:
- a) an effective amount of an ectoparasitocidal combination consisting of fipronil and amitraz;
 - b) wherein the carrier includes di-ethylene glycol monomethyl ether and ethanol; and
 - c) optionally, a crystallization inhibitor.
- 54-55. (Cancelled)